Annexon Bioscience racks up $34 mln

By Iris Dorbian — 1 year ago

Annexon Bioscience has raised $34 million in Series A-1 funding. Novartis Venture Funds led the round with participation from Satter Investment Management and Clarus Ventures. Based in Redwood City, Calif., Annexon Bioscience is a developer of pathway inhibitors that treat neurodegenerative and autoimmune diseases.

Continue

Advanced Animal Diagnostics closes $15 mln Series C funding

By Chris Witkowsky — 1 year ago

Advanced Animal Diagnostics, which makes on-farm diagnostic technologies, has raised $15 million in Series C funding co-led by Cultivian Sandbox and Kansas Bioscience Authority. The funding round included Laboratory Corporation of America Holdings, Middleland Capital and existing investors Intersouth Partners, Novartis Venture Funds and private individuals.

Continue

Aileron Therapeutics grabs $33 mln Series E

By Iris Dorbian — 1 year ago

Aileron Therapeutics has raised $33 million in Series E funding. The investors included AJU IB Investment Co., Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One. Based in Cambridge, Mass., Aileron Therapeutics is a clinical stage biopharmaceutical firm that is developing therapeutics based on its proprietary Stapled Peptide drug platform.

Continue

Quartet Medicine scores $17 mln Series A

By Iris Dorbian — 1 year ago

Quartet Medicine has closed $17 million in Series A financing. Atlas Venture led the round with participation from Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund. In conjunction with the funding, Henry Skinner of Novartis Venture Funds has been appointed to Quartet’s board of directors. Based in Cambridge, Mass., Quartet is a biotech firm focused on treating chronic pain and inflammation.

Continue

VC-backed Sorbent Therapeutics expands board of directors

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Sorbent Therapeutics closes first tranche in $15 mln Series D

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has closed a $6.5 million tranche in a $15 million Series D financing. The investors were CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Atlas Genetics nabs Series B funds

By Iris Dorbian — 2 years ago

Atlas Genetics has raised 16.9 million pounds in Series B funding. The investors in this round include Novartis Venture Funds, Consort Medical plc, Life Sciences Partners, BB Biotech Ventures, Johnson & Johnson Development Corp. and YFM Equity Partners. Based in Bath, England, Atlas is a diagnostics company that provides tests for infectious diseases.

Continue

Aerpio Therapeutics grabs $22 mln

By Iris Dorbian — 2 years ago

Aerpio Therapeutics said Wednesday that it has raised $22 million in funding. OrbiMed led the round with participation from return backers Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon Medical Ventures and Athenian Venture Partners. In addition to the funding, OrbiMed’s Chau Q. Khuong has been added to Aerpio’s board of directors. Based in Cincinnati, Aerpio Therapeutics is a biopharmaceutical firm focused on therapies for vascular diseases.

Continue

VC-backed Akebia Therapeutics launches IPO

By Iris Dorbian — 2 years ago

Akebia Therapeutics has launched its IPO of over 5.8 million shares at $17 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AKBA.” Morgan Stanley, Credit Suisse and UBS Investment Bank are the lead underwriters. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer. Its backers include Satter Investment Management, Novo A/S, Novartis Venture Funds, Kearny Venture Partners, Athenian Venture Partners and Triathlon Medical Ventures.

Continue

Aileron Therapeutics secures new financing

By Angela Sormani — 2 years ago

Aileron Therapeutics has secured $30 million in Series E equity financing from investors including Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Excel Venture Management. The clinical stage biopharmaceutical company is developing therapeutics based on its proprietary Stapled Peptide drug platform.

Continue

eFFECTOR Therapeutics Raises $45 Million Series A

By Angela Sormani — 3 years ago

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Continue

Tokai Pharmaceuticals Inks $35.5m Series E

By Angela Sormani — 3 years ago

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $35.5 million in a Series E financing. The financing round included both current investors, Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.

Continue

Celladon Wraps Up $43M Round

By Staff Report — 4 years ago

Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson […]

Continue

Takeda Pharmaceutical Buys VC-Backed Intellikine

4 years ago

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Continue

Intellikine Adds $4M in Milestone Payments

4 years ago

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Continue

Advanced Animal Diagnostics Inks $11M

5 years ago

Advanced Animal Diagnostics, a developer of technologies to diagnose farm animal diseases, has closed on $11 million in Series B financing. Intersouth Partners led the round, which included participation from Novartis Venture Funds and other, unnamed investors. The company will use the financing to continue development of its diagnostic tests. Advanced Animal’s first on-farm product will focus on improving milk production and quality by controlling mastitis, an infection of the milk-producing gland of cows.

Continue